Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter D Senter

Showing results (11-20 of 83) with videos related to

Pageof 9
Sort By:
Nature Chemical Biology|August 28, 2019
Breaking up is hard to doHeather A Van Epps, Peter D Senter
Hematology/Oncology Clinics of North America|November 30, 2013
Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drugNicole M Okeley, Stephen C Alley, Peter D Senter
Mabs|January 15, 2010
Antibody drug-conjugates targeting the tumor vasculature: Current and future developmentsHans-Peter Gerber, Peter D Senter, Iqbal S Grewal
Current Opinion in Chemical Biology|July 21, 2010
Antibody-drug conjugates: targeted drug delivery for cancerStephen C Alley, Nicole M Okeley, Peter D Senter
Molecular Pharmaceutics|May 13, 2009
Meeting report: International Symposium on Intelligent Drug Delivery Systems South Korea, 2008Yu-Kyoung Oh, Peter D Senter, Soo-Chang Song
Bioconjugate Chemistry|September 5, 2009
Intelligent drug delivery systemsYu-Kyoung Oh, Peter D Senter, Soo-Chang Song
Proceedings of the National Academy of Sciences of the United States of America|September 5, 2014
A previously undescribed tubulin binderJessica J Field, Andrew B Waight, Peter D Senter
Molecular Pharmaceutics|October 8, 2010
Meeting report: International Symposium on Intelligent Drug Delivery Systems, 2010Youngro Byun, Yu-Kyoung Oh, Peter D Senter, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Expanded Utility of the β-Glucuronide Linker: ADCs That Deliver Phenolic Cytotoxic AgentsScott C Jeffrey, Jef De Brabander, Jamie Miyamoto, et al.
The Journal of Organic Chemistry|March 16, 2002
Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugsBrian E Toki, Charles G Cerveny, Alan F Wahl, et al.
Pageof 9

Showing results (11-20 of 83) with videos related to

Sort By:
Pageof 9
Nature Chemical Biology|August 28, 2019
Breaking up is hard to doHeather A Van Epps, Peter D Senter
Hematology/Oncology Clinics of North America|November 30, 2013
Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drugNicole M Okeley, Stephen C Alley, Peter D Senter
Mabs|January 15, 2010
Antibody drug-conjugates targeting the tumor vasculature: Current and future developmentsHans-Peter Gerber, Peter D Senter, Iqbal S Grewal
Current Opinion in Chemical Biology|July 21, 2010
Antibody-drug conjugates: targeted drug delivery for cancerStephen C Alley, Nicole M Okeley, Peter D Senter
Molecular Pharmaceutics|May 13, 2009
Meeting report: International Symposium on Intelligent Drug Delivery Systems South Korea, 2008Yu-Kyoung Oh, Peter D Senter, Soo-Chang Song
Bioconjugate Chemistry|September 5, 2009
Intelligent drug delivery systemsYu-Kyoung Oh, Peter D Senter, Soo-Chang Song
Proceedings of the National Academy of Sciences of the United States of America|September 5, 2014
A previously undescribed tubulin binderJessica J Field, Andrew B Waight, Peter D Senter
Molecular Pharmaceutics|October 8, 2010
Meeting report: International Symposium on Intelligent Drug Delivery Systems, 2010Youngro Byun, Yu-Kyoung Oh, Peter D Senter, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Expanded Utility of the β-Glucuronide Linker: ADCs That Deliver Phenolic Cytotoxic AgentsScott C Jeffrey, Jef De Brabander, Jamie Miyamoto, et al.
The Journal of Organic Chemistry|March 16, 2002
Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugsBrian E Toki, Charles G Cerveny, Alan F Wahl, et al.
Pageof 9